Project: A novel diagnostic assay to stratify lung cancer patients with EGFR therapy resistance.
A deletion in the proto-oncogene MET (delta78MET) causes MET activation and resistance to EGFR inhibitors which presents a major clinical problem. DELTAMET will validate delta78MET as a novel predictive biomarker and delivers a novel diagnostic assay which accurately predicts resistance to EGFR inhibitors in advanced lung cancer patients with aberrant MET activation and the first companion diagnostic assay able to stratify patients responsive to MET inhibitors for personalised medicine.
| Acronym | DELTAMET (Reference Number: 9616) |
| Duration | 01/10/2015 - 01/10/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 3 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 21084 | thromboDx | Coordinator | Netherlands |
| 21085 | Radboud UMC | Partner | Netherlands |
| 21086 | Pangaea Biotech | Partner | Spain |